Additionally, compared to non-tumor tissue samples, STC2 expression was high in 15.8% (47/298), moderate in 54.7% (163/298), and weak in 29.5% (86/298) of HNSCC cases (Figure 6B). This evidence concerns the gene STC2 and neoplasm.